{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:32Z","timestamp":1784926832749,"version":"3.55.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Unresectable, locally advanced nonsmall cell lung cancer (LA\u2011NSCLC) accounts for \u223c20% to 30% of newly diagnosed cases of NSCLC and remains associated with poor long\u2011term outcomes. Concurrent chemoradiotherapy (cCRT) has long been the therapeutic backbone for unresectable stage III disease, and the addition of consolidative durvalumab represents a major advance, significantly improving progression\u2011free and overall survival. Nonetheless, early progression and treatment\u2011related toxicity limit benefit for many patients, prompting investigation into alternative immunotherapy sequencing and escalation strategies. To date, randomized trials evaluating concurrent immune checkpoint blockade or intensified consolidation have not demonstrated additional survival benefit. In contrast, emerging precision\u2011medicine approaches\u2014including consolidative targeted therapy for oncogene\u2011driven tumors\u2014have yielded profound improvements in selected populations. Concurrently, advances in radiation delivery emphasize individualized strategies to optimize local control while minimizing toxicity. This review summarizes evolving systemic and radiation\u2011based approaches for LA\u2011NSCLC, highlighting current limitations and future directions to improve outcomes.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000836","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:11Z","timestamp":1784923211000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing the Care of Patients With Locally Advanced NSCLC With Multimodality Therapy"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-7746","authenticated-orcid":false,"given":"Mohammed","family":"Mohammed","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal S.","family":"McCall","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Higgins","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope, Newnan, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"key":"R2-20260724","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199202203260805","article-title":"Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer","volume":"326","author":"Schaake-Koning","year":"1992","journal-title":"N Engl J Med"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM199010043231403","article-title":"A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer","volume":"323","author":"Dillman","year":"1990","journal-title":"N Engl J Med"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jnci\/87.3.198","article-title":"Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer","volume":"87","author":"Sause","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jnci\/83.6.417","article-title":"Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients","volume":"83","author":"Le Chevalier","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential versus concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"JCO"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.07.3569","article-title":"Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B","volume":"25","author":"Vokes","year":"2007","journal-title":"JCO"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1200\/JCO.2008.17.7840","article-title":"Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology","volume":"26","author":"Hanna","year":"2008","journal-title":"JCO"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2014.60.0130","article-title":"Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04","volume":"33","author":"Ahn","year":"2015","journal-title":"JCO"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"JCO"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.resinv.2019.03.011","article-title":"Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria","volume":"57","author":"Sakaguchi","year":"2019","journal-title":"Respir Investig"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2019.11.015","article-title":"Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer","volume":"144","author":"Shaverdian","year":"2020","journal-title":"Radiother Oncol"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"586449","DOI":"10.3389\/fonc.2020.586449","article-title":"Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer: cross-sectional study of eligibility and administration rates","volume":"10","author":"Eichkorn","year":"2020","journal-title":"Front Oncol"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage III non-small cell lung cancer: a phase II nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1038\/s41467-025-66097-w","article-title":"Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial","volume":"16","author":"Provencio","year":"2025","journal-title":"Nat Commun"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jtho.2025.09.020","article-title":"PL03.06 EA5181: phase 3 trial of concurrent and consolidative durvalumab versus consolidation durva alone for unresectable stage 3 NSCLC","volume":"20","author":"Varlotto","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R22-20260724","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.iotech.2024.100808","article-title":"65O CheckMate 73L: phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC","volume":"24","author":"Peters","year":"2024","journal-title":"Immuno-Oncology and Technology"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/j.cllc.2022.04.003","article-title":"Rationale and design of the phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage III non-small-cell lung cancer","volume":"23","author":"Jabbour","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"e2518440","DOI":"10.1001\/jamanetworkopen.2025.18440","article-title":"Durvalumab alone or combined with novel agents for unresectable stage III non-small cell lung cancer: update from the COAST randomized clinical trial","volume":"8","author":"Aggarwal","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"S1725","DOI":"10.1016\/j.annonc.2025.09.081","article-title":"LBA69 SKYSCRAPER-03: Phase III, open-label, randomized study of atezolizumab (atezo) + tiragolumab (tira) versus durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT)","volume":"36","author":"Dziadziuszko","year":"2025","journal-title":"Ann Oncol"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO-25-01569","article-title":"Chemoradiation \u00b1 Atezolizumab in limited-stage small cell lung cancer: results of NRG Oncology\/Alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2022.07.015","article-title":"Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era","volume":"174","author":"McCall","year":"2022","journal-title":"Radiother Oncol"},{"key":"R31-20260724","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/1759-7714.14448","article-title":"Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations","volume":"13","author":"Uehara","year":"2022","journal-title":"Thorac Cancer"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"R36-20260724","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jtho.2024.01.012","article-title":"Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: a multicenter retrospective cohort study","volume":"19","author":"Nassar","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"suppl 16","key":"R37-20260724","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1200\/JCO.2022.40.16_suppl.8541","article-title":"Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: a post hoc subgroup analysis from PACIFIC","volume":"40","author":"Naidoo","year":"2022","journal-title":"JCO"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/03008916221122601","article-title":"Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD (L)1 agents: a systematic review","volume":"109","author":"Luciani","year":"2023","journal-title":"Tumori"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R40-20260724","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"R41-20260724","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.annonc.2024.08.2243","article-title":"Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study*","volume":"35","author":"Lu","year":"2024","journal-title":"Ann Oncol"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jtho.2024.09.021","article-title":"PL04.13 aumolertinib maintenance after chemoradiotherapy in stage III non-small-cell lung cancer: interim results of the phase III study (POLESTAR)","volume":"19","author":"Yu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1016\/j.jtho.2024.09.614","article-title":"P3.08F.08 NEOLA: phase II study of osimertinib treatment before and after chemoradiotherapy in unresectable stage III EGFRm NSCLC","volume":"19","author":"Wakelee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R44-20260724","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jtho.2024.09.1379","article-title":"Consolidation ALK tyrosine kinase inhibitors versus durvalumab or observation after chemoradiation in unresectable stage III ALK-positive NSCLC","volume":"20","author":"Nassar","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"JCO"},{"key":"R47-20260724","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamaoncol.2024.1841","article-title":"Long-term prospective outcomes of intensity modulated radiotherapy for locally advanced lung cancer: a secondary analysis of a randomized clinical trial","volume":"10","author":"Chun","year":"2024","journal-title":"JAMA Oncol"},{"issue":"suppl 17","key":"R49-20260724","doi-asserted-by":"crossref","first-page":"LBA8069","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8069","article-title":"Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial","volume":"42","author":"Schytte","year":"2024","journal-title":"JCO"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.ijrobp.2024.07.1917","article-title":"NRG LU008: phase III prospective randomized trial of primary lung tumor stereotactic body radiation therapy (SBRT) followed by concurrent mediastinal chemoradiation for locally-advanced non-small cell lung cancer (LA-NSCLC)","volume":"120","author":"Simone","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R51-20260724","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: a randomized phase II trial of individualized adaptive (chemo) radiotherapy using midtreatment 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in stage III non-small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"J Clin Oncol"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijrobp.2025.01.005","article-title":"Randomized evaluation of the PET-adjusted IMRT for NSCLC Trial (REPAINT)","volume":"122","author":"Ohri","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R53-20260724","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1200\/JCO-24-01386","article-title":"Toxicity within 6 months of heterogeneous fluorodeoxyglucose-guided radiotherapy dose escalation for locally advanced non-small cell lung cancer in the Scandinavian randomized phase III NARLAL2 trial","volume":"43","author":"Schytte","year":"2025","journal-title":"J Clin Oncol"},{"key":"R54-20260724","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.21873\/anticanres.14339","article-title":"Pattern of local failure and its risk factors of locally advanced non-small cell lung cancer treated with concurrent chemo-radiotherapy","volume":"40","author":"Abe","year":"2020","journal-title":"Anticancer Res"},{"key":"R55-20260724","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R56-20260724","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ijrobp.2014.05.135","article-title":"Long-term Results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer","volume":"90","author":"Timmerman","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R57-20260724","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable stage III non-small cell lung cancer: a phase I study","volume":"12","author":"Higgins","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1748-717X-8-179","article-title":"Dose escalation with stereotactic body radiation therapy boost for locally advanced non-small cell lung cancer","volume":"8","author":"Karam","year":"2013","journal-title":"Radiat Oncol"},{"key":"R59-20260724","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2016.08.032","article-title":"Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non-small cell lung cancer: a phase 1 dose escalation study","volume":"96","author":"Hepel","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R60-20260724","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumor stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"key":"R61-20260724","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2025.09.016","article-title":"Primary tumor failure after definitive chemoradiation in locally advanced non-small cell lung cancer: a brief report on the implications for NRG LU-008","volume":"124","author":"Friedes","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R62-20260724","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2016.07.025","article-title":"Stage III non-small cell lung cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice","volume":"121","author":"Driessen","year":"2016","journal-title":"Radiother Oncol"},{"key":"R63-20260724","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdn559","article-title":"Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study","volume":"20","author":"De Ruysscher","year":"2009","journal-title":"Ann Oncol"},{"key":"R64-20260724","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R65-20260724","doi-asserted-by":"crossref","first-page":"105071","DOI":"10.1016\/j.esmoop.2025.105071","article-title":"Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer\u2014final analysis from the phase II PACIFIC-6 trial","volume":"10","author":"Garassino","year":"2025","journal-title":"ESMO Open"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:19Z","timestamp":1784923219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000836","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}